Mizuho Securities analyst Ann Hynes has maintained their bullish stance on HUM stock, giving a Buy rating on February 11.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Ann Hynes’s rating is based on Humana’s strong financial performance and future growth potential. The company reported solid quarterly earnings, with adjusted EPS exceeding consensus estimates, indicating strong financial health. Additionally, Humana’s revenue growth and its ability to meet or exceed its guidance targets further support the Buy rating.
Despite anticipating a decline in Medicare Advantage membership, Humana has provided reassuring guidance for 2025, with expectations of stable earnings and revenue growth. The company’s strategic investments, particularly in improving its Stars ratings, and its focus on maintaining or improving margins, contribute positively to the overall outlook. Ann Hynes believes that with continued execution, Humana is well-positioned for future success, justifying the Buy rating.
Hynes covers the Healthcare sector, focusing on stocks such as Quest Diagnostics, Walgreens Boots Alliance, and IQVIA Holdings. According to TipRanks, Hynes has an average return of 9.3% and a 58.70% success rate on recommended stocks.
In another report released on February 11, RBC Capital also maintained a Buy rating on the stock with a $283.00 price target.